Full Breakdown
Investigation into FDA's Denials of Rare Disease Treatments
3/11/2026, 10:57:28 AM
Core Event: Senator Ron Johnson's Inquiry into FDA Drug Approval Process
Wisconsin Senator Ron Johnson has initiated an investigation into the Food and Drug Administration's (FDA) recent denials of treatments for rare diseases, a move that adds political pressure to an agency already facing scrutiny. Johnson, who chairs the Senate's Permanent Subcommittee on Investigations, is seeking the FDA's complete response letters to drug manufacturers and may call top FDA officials, including Commissioner Marty Makary, to testify. This investigation follows the FDA's refusal to approve several treatments, including a gene therapy for Huntington's disease developed by UniQure NV, which Johnson criticized as “bureaucratic idiocy.”
Background & Context: Recent FDA Actions and Industry Response
The FDA has faced backlash from patient advocates and biotech companies for its stringent requirements regarding drug approvals. Critics argue that the agency has shifted its standards, making it more difficult for new therapies to gain approval. Johnson has been a long-time advocate for access to experimental drugs, previously sponsoring the Right to Try Act in 2018 to facilitate access for terminally ill patients. His recent involvement includes efforts to restore access to a gene therapy for Duchenne muscular dystrophy (DMD) after the FDA requested its withdrawal following adverse events.
Official Statements & Responses
In response to Johnson's allegations, Andrew Nixon, a spokesperson for the Department of Health and Human Services, stated that the FDA stands by its scientists and that the rationale for drug approvals and rejections is detailed in the complete response letters, which are now publicly available. Nixon emphasized that the number of approvals and rejections under the current administration aligns with historical data and that the FDA is committed to expediting the development of treatments for ultra-rare diseases.
Criticism & Opposition: Concerns Over Political Interference
While Johnson's investigation aims to hold the FDA accountable, some experts express concern about the implications of congressional pressure on specific drug decisions. Holly Fernandez Lynch, an associate professor of medical ethics at the University of Pennsylvania, cautioned that while oversight is essential, interference could undermine public trust in the FDA's decision-making process. Critics argue that drug approval decisions should be based on scientific data rather than political influence.
Conflicting Reports & Gaps: Discrepancies in FDA's Justifications
The FDA's insistence on additional studies for drugs like UniQure's AMT-130 has been met with skepticism. The agency has stated that it requires a randomized, sham-controlled trial to validate the therapy's efficacy, a request that some, including Johnson, view as excessive. The FDA has also faced criticism for its handling of the application for ataluren, a treatment for DMD, which was withdrawn by PTC Therapeutics after the agency indicated it did not meet the necessary evidence threshold for approval.
Verbatim Quotes
- “It just appears that they’re looking for excuses to say no.” — Senator Ron Johnson
- “Our obligation is to patients and public health, and we remain committed to a regulatory approach that brings safe, effective individualized treatments to patients who urgently need them.” — Andrew Nixon, HHS Spokesperson
- “Oversight is important, but interference is worrisome,” — Holly Fernandez Lynch, Associate Professor of Medical Ethics
Senator Johnson's investigation reflects ongoing tensions between regulatory practices and the urgent needs of patients with rare diseases, highlighting the complexities of drug approval processes in the U.S.
